May 2026
Great experience
Great experience with ordering. Great delivery.
Yah's Atarah· US Verified
sexual-health
Research Use OnlyPT-141
5.0 · 1 reviewAll Gender Sexual Arousal
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-MSH. Investigated in pre-clinical literature as a non-selective melanocortin receptor agonist with characterized action on the MC3R and MC4R signaling pathways. Sold for laboratory research and identification purposes only. Not for human consumption.
Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
$195One-time
Quantity
1
Free shipping over $500
HPLC VerifiedPublished COAUSA · Cold-Chain
Paying by Zelle / Apple Cash
New to sending payment this way? It's quick, and your order is protected:
- Payment confirmed as soon as it lands — usually within minutes during business hours.
- Most orders ship the same day, cold-packed and discreet.
- Every order ships tracked, with an email at each step.
- Questions answered within hours by a real person.
If we ever can't fulfill your order, you're refunded within 1–2 business days.
PT-141
$195
Technical Data
Specifications
Specifications
Technical Details
01
Purity99%+ (HPLC)
02
FormLyophilized Powder
03
StorageStore at -20°C. Reconstituted: 2–8°C, use within 14 days.
04
Dosage1–2 mg subcutaneous administration in research models; intranasal dosing also documented
05
FormatLyophilized
06
SourceSynthetic
07
SequenceAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
08
Half-Life~2.7 hours
09
CAS Number189691-06-3
10
Molecular Weight1025.18 Da
11
Receptor TargetsMC3R, MC4R (primary)
12
Molecular FormulaC₅₀H₆₈N₁₄O₁₀
Quality Assurance
Certificate of Analysis
Certificate of Analysis
Verified Feedback
Reviews
5.0
1 verified review
5★
1
4★
0
3★
0
2★
0
1★
0
1 review
Research Overview
About PT-141
PT-141 (bremelanotide) is a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH) that acts as a selective agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike phosphodiesterase-5 inhibitors that operate through peripheral vascular smooth muscle relaxation, PT-141's mechanism is fundamentally central — activating dopaminergic and oxytocinergic pathways within the hypothalamus that govern sexual motivation and arousal response.
Clinical research has been conducted across both male and female populations, with significant attention to hypoactive sexual desire disorder (HSDD) in women — a condition where the central, non-vascular mechanism offers theoretical advantages over peripherally acting agents. The compound's receptor selectivity profile was refined from its precursor Melanotan II through structural optimization to minimize off-target melanocortin effects.
ROEHN supplies PT-141 at 99% HPLC-verified purity as a lyophilized powder. It is available in both injectable and nasal spray formats, supporting research protocols investigating melanocortin receptor pharmacology, central arousal circuitry, and gender-inclusive sexual function endpoints.
